The NHIS will begin research on improving the PVA system

Director Kim Hyun-deok said, "It is difficult to raise the amount excluding PVA to 5 billion won and 10 billion won at once"

Manager Kim Hyunduk

Health insurance authorities have announced plans to place an order for research services to evaluate the PVA system and prepare improvement measures.

 

It is said that it will further specify the targets for drug cuts and health insurance financial savings through PVA as large items.

 

However, she replied that it is difficult to accept immediately the standard for PVA exclusion from the current 1.5 billion won to 5 billion won or 10 billion won desired by the pharmaceutical industry.

 

On the 25th, Kim Hyun-deok made the remarks at the National Assembly's policy meeting on "Rational Improvement Plan for PVA." The NHIS said the pharmaceutical industry, pharmaceutical society, the National Assembly, and the Board of Audit and Inspection have agreed on the need to improve the PVA system, one of the ways to reduce drug costs.

 

Kim said she is pursuing the direction of discussions on PVA amendments targeting large items and plans to order research services to prepare overall system improvement measures.

 

Director Kim said that she is aware of the problem of applying the PVA cut formula to all medicines collectively regardless of the absolute amount of increase.

 

Director Kim said, "We are aware of the industrial problem of reviewing only the growth rate without taking into account the absolute increase in claims," adding, "We agree that it is necessary to evaluate PVA in general and prepare improvements." We plan to order research services this year, she explained.

 

Director Kim said, "Many demands for PVA improvement have been raised not only by pharmaceutical and pharmacist societies, but also by the Board of Audit and Inspection and Inspection, no matter how much use increases, it is unreasonable to limit it to 10% with PVA.

 

We will review it through research, she said.

 

"The study also plans to discuss changing the standard amount excluding PVA from 1.5 billion won to 2 billion won, but we have to go step by step," she said adding, "The pharmaceutical community talks about 5 billion won and 10 billion won, but it is difficult to go so quickly." It was originally scheduled to take effect on January 1 this year, but it seems to have been delayed to collect opinions from the pharmaceutical industry, she added.